Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.

Moore, Kathleen; Colombo, Nicoletta; Scambia, Giovanni; Kim, Byoung-Gie; Oaknin, Ana; Friedlander, Michael; Lisyanskaya, Alla; Floquet, Anne; Leary, Alexandra; S Sonke, Gabe; Gourley, Charlie; Banerjee, Susana; Oza, Amit; González-Martín, Antonio; Aghajanian, Carol; Bradley, William; Mathews, Cara; Liu, Joyce; S Lowe, Elizabeth; Bloomfield, Ralph; DiSilvestro, Paul

doi:10.1056/nejmoa1810858

Public

Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.

Published in The New England journal of medicine • Dec 27, 2018

NobleIDark:/48914/w1/20260526/79E78CF1Record on NobleID

Authors:

Kathleen Moore

,

Nicoletta Colombo

,

Giovanni Scambia

Abstract

BACKGROUND: Most women with newly diagnosed advanced ovarian cancer have a relapse within 3 years after standard treatment with surgery and platinum-based chemotherapy. The benefit of the oral poly(adenosine diphosphate-ribose) polymerase inhibitor olaparib in relapsed disease has been well establis...

Discussions